This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
by Zacks Equity Research
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
by Zacks Equity Research
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
by Zacks Equity Research
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
by Zacks Equity Research
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
by Zacks Equity Research
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
by Kanishka Das
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?
by Kanishka Das
Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
by Zacks Equity Research
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
by Zacks Equity Research
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
The Zacks Analyst Blog Highlights NVIDIA, Roche, Lam Research, Tredegar and Kewaunee Scientific
by Zacks Equity Research
NVIDIA, Roche, and Lam Research lead this week's top Zacks research picks, while Tredegar and Kewaunee Scientific highlight strong niche and microcap opportunities.
Top Stock Reports for NVIDIA, Roche & Lam Research
by Mark Vickery
NVIDIA, Roche, and Lam Research lead today's top Zacks reports, showcasing standout growth drivers and sector-specific strengths.
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
by Kanishka Das
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
by Zacks Equity Research
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
by Sundeep Ganoria
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
by Zacks Equity Research
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
by Kanishka Das
MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
by Zacks Equity Research
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
by Zacks Equity Research
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
by Kanishka Das
Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
by Zacks Equity Research
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
by Zacks Equity Research
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.